Clinical trials: PEComa
Kidney Neoplasms
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
The knowledge of the histological diagnosis and its subtype of a renal parenchymal tumor is important for determine whether the choice of a specific regimen of chemotherapy, target therapy and immunotherapy could be suitable and…
- Trial name
- NCT06126159
- Testing
- multiparametric and fat-detection magnetic resonance imaging (MRI)
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- Chang Gung Memorial Hospital
PEComa, Hemangioma
Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors
PEComa is rare tumor affecting particularly patients with Tuberous Sclerosis. Biological similarities were seen between PEComa and infantile hemangioma.
- Trial name
- PEC-Hem (NCT02334930)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 13 people
- Sponsor
- University Hospital, Bordeaux
Lymphangioleiomyomatosis
Discovery of Sirolimus Sensitive Biomarkers in Blood
Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive disease. It usually affects women in the prime of their lives. It typically results in lung destruction.
- Trial name
- NCT03304678
- Testing
- Sirolimus 2mg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that appears to behave like a slowly growing cancer. Since clinical progression is very slow, new blood tests have been used to speed the time required to find safe and…
- Trial name
- LAMP-2 (NCT06889168)
- Testing
- Imatimib Mesylate
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
LAM, Lymphangioleiomyomatosis
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.
- Trial name
- MILED (NCT03150914)
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Cincinnati
Lymphangioleiomyomatosis, LAM
Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM)
Data from patients with the orphan disease of lymphangioleiomyomatosis (LAM) which performed a pulmonary Rehabilitation program will be analyzed retrospectively.
- Conditions
- Lymphangioleiomyomatosis, LAM, Pulmonary Rehabilitation
- Trial name
- NCT04184193
- Testing
- Pulmonary Rehabilitation
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Malignant PEComa
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
- Trial name
- AMPECT (NCT02494570)
- Testing
- nab-Sirolimus
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aadi Bioscience, Inc.
Tuberous Sclerosis Complex, Lymphangioleiomyomatosis
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
- Trial name
- NCT06160310
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- David M. Ritter
Lymphangioleiomyomatosis
Efficacy and Safety of Sirolimus in LAM
Lymphangioleiomyomatosis (LAM) is a rare lung disease of women that is caused by genetic mutations. It results in the uncontrolled growth of an unusual type of smooth muscle cell in the lung.
- Trial name
- MILES (NCT00414648)
- Testing
- Sirolimus
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 89 people
- Sponsor
- University of Cincinnati
Lung Disease, Pneumothorax
Study of the Disease Process of Lymphangioleiomyomatosis
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.
- Conditions
- Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis
- Trial name
- NCT00001465
- Testing
- Toshibia Aquilion One CT
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)